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Drug-eluting stents have revolutionised the treatment of coronary artery disease. These small medical
devices have attracted much interest over the past decade from biologists, clinicians, engineers and
mathematicians alike. This article provides a comprehensive review of the modelling of drug release from
arterial stents and the subsequent drug transport through arterial tissue, and acts as a useful reference
equally for those who are already involved in drug-eluting stents research and for those who are starting
out in the ﬁeld. Assembled in this review are the main models of drug release and arterial drug transport
that have been published in the literature to date. Many of the models presented in this paper have
evolved from drug transport models in other applications. Furthermore, the ideas presented in this
review may also be extended to other drug-delivery applications, such as drug coated balloons, transder-
mal patches and therapeutic contact lenses.
 2014 The Author. Published by Elsevier Inc. This is an open access article under the CC BY license (http://
creativecommons.org/licenses/by/3.0/).1. Introduction and Background Scientiﬁc Corporation) arrived. They comprised a stainless steelArterial stents have revolutionised the treatment of coronary
heart disease (CHD). Acting as a supporting scaffold, these small
mesh devices are now routinely inserted into arteries where the
blood ﬂow has become dangerously restricted (see Fig. 1). There
are many beneﬁts to the patient over more traditional treatment
strategies such as open-heart surgery, including a lower incidence
of major complications and an expedited recovery time. Further-
more, most patients do not require general anesthesia. Over the
past decade, arterial stents have evolved from mere bare metal
scaffolds to polymer coated drug-delivery vehicles and, more
recently, sophisticated fully biodegradable drug delivery conﬁgu-
rations. The driver behind these continuing advances is the desire
to improve clinical outcomes. The original bare metal stents, while
revolutionary at the time, were soon rendered unsatisfactory due
to the relatively quick occurrence of restenosis, the re-narrowing
of the lumen. The next wave of arterial stents included a drug
designed to prevent the occurrence of restenosis: these are the
so-called drug-eluting stents (DESs). The development of these
stents threw up all sorts of questions such as: What type of drug
should be used? How much drug should be coated on the stent?
How will the drug release be controlled? Effective DES design
became the priority for many of the top medical device companies,
with considerable budgets spent on developing these products. In
2002 the ﬁrst-generation DESs, Cypher (sirolimus-eluting stent;
Cordis Corporation) and Taxus (paclitaxel-eluting stent; Bostonplatform with a drug containing polymer coating attached to the
stent struts [1,2]. The philosophy behind this design was to allow
the drug to be released gradually so as to avoid toxic levels of drug
initially, but also to permit sustained delivery over many weeks.
The Cypher stent actually consists of multiple polymer layers
designed to enhance the controlled nature of the release. The drugs
used (sirolimus and paclitaxel) are both lipophilic and are able to
inhibit smooth muscle cell (SMC) proliferation and migration.
The second-generation DESs Endeavor (zotarolimus-eluting;
Medtronic), Promus (everolimus-eluting; Boston Scientiﬁc
Corporation) and Xience V (everolimus eluting; Abbott Laborato-
ries) attempted to improve the biocompatibility and reduce the
incidence of thrombosis which was associated with ﬁrst-genera-
tion DES [3,4]. These stents were generally designed with thinner
struts and utilised cobalt-chromium and platinum chromium plat-
forms. A variety of multi-layer polymer combinations were used on
these stents to attempt to control the release. Generally these
stents have been shown to exhibit lower thrombosis rates com-
pared with ﬁrst generation DES [5]. Since the polymer coating in
the earlier DES has been associated with a local vascular inﬂamma-
tory reaction and potentially inducing late stent thrombosis, newer
generation stents have focussed on biodegradable polymers (BioM-
atrix, Biosensors Inc, Nobori, Terumo, and Synergy, Boston Scien-
tiﬁc Corporation), where the polymer carries and controls the
drug release and then erodes or vanishes, and also coatings which
do not contain any polymer at all (Yukon, Translumina and
BioFreedom, Biosensors Inc), with the drug being contained on a
modiﬁed surface of the stent. Perhaps the most sophisticated
to date is the completely bioresorbable stent Absorb (Abbott
Fig. 1. Illustration of a stent being inserted at the site of a blocked artery. Source: National Heart, Lung and Blood Institute; National Institute of Health; U.S. Department of
Health and Human Services.
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Xience V and then resorbs naturally into the body leaving no
permanent scaffold.
A signiﬁcant amount of research has gone into the development
of arterial stents. Countless experiments have been performed
(many of which involving animals), not to mention the need for
clinical trials before accreditation is ﬁnally granted. The long
treacherous and costly road from a good stent design idea to regu-
latory approval has led many to question whether modelling could
be better used to try to make this path an easier one. Indeed, only
those stents which show promising results in laboratory and clin-
ical trials are retained and those that do not are discarded – often
after considerable investment. Mathematicians and engineers,
realising that this complex problem is amenable to modelling, have
become increasingly interested over the years. In the early years
the drug release mechanism was very poorly understood, but
through mathematical modelling approaches, combined with
experiments, researchers have helped identify the dominant
mechanisms of release in a number of stents. While release exper-
iments alone can give information regarding the release proﬁle and
the duration of release, the data generated is for one particular set
of parameters (e.g. coating thickness, drug type and concentration)
and the experiment needs to be repeated for each new parameter
considered. Once veriﬁed, mathematical models have the advan-
tage of allowing several parameters to be varied and the release
proﬁles compared without the need to repeat the experiments.
The ability of a mathematical model to help identify the important
parameters that govern the drug release is invaluable. Modelling
can also play an important role when an understanding of the drug
distribution within arterial tissue is required. Cardiologists will
often stress that uniform drug concentrations across the wall are
desired, and that these concentrations should be maintained
within some minimum therapeutic and toxic levels. Obtaining this
kind of information from experiments is extremely challenging, yet
free and bound drug concentration proﬁles can readily be output
from a mathematical model. But experiments and modelling must
go hand in hand: the accuracy of the model results can only ever be
as good as the quality of the inputs, especially when the model issensitive to changes in one or more of the parameters. Indeed,
the accurate determination of system parameters remains one of
the biggest challenges in the ﬁeld due to the natural variation
between species and the complexity involved in making the
required measurements, especially in the in vivo situation.
However, some recent progress has been made by combining
in vitro/ex vivo experiments with simple mathematical models,
and this approachmay continue to yield useful results in the future.
Aswe shall see, the conclusionswhich can be drawn frommodelling
have provided useful insights, some of which are counter-intuitive.
Among the many other beneﬁts of adopting a modelling approach
include the potential to indicate at an early stage the designs that
are doomed to failure, to design stents that are optimised and to
result in a reduction in the number of experiments required.
In this paper we provide a comprehensive review of the model-
ling of drug-release from arterial stents and the subsequent arterial
drug redistribution. We ﬁrstly present the models which have been
developed to describe drug release from DESs. Then, we consider
how drug uptake into arterial tissue has been modelled. Thirdly,
models which treat the stent and the arterial wall as a coupled
system are reported. The beneﬁts and drawbacks of each model
are discussed. We have attempted to unite the various different
notations in the literature. With this in mind, the models presented
here may differ in notation from the original work.2. Modelling the release of drug from arterial stents
An important aspect in the performance of any DES is the drug
release proﬁle. If too much drug is delivered then toxicity can arise,
whereas if too little drug is delivered then it may have no effect at
all. Of course, this ‘‘therapeutic window’’ varies between drugs and
between patients and most probably with time after implantation
too. Stent manufacturers routinely test the release of drug from
their stents in an in vitro environment to gain an understanding
of the shape of the release proﬁle and to compare the release pro-
ﬁle of different devices. This allows the manufacturers to ascertain
the repeatability of the release proﬁle. Whilst the in vitro release is
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important step in the development process. From the modelling
perspective it makes sense to start with simple models, and in
particular, it seems sensible to ﬁrstly consider modelling release
in a controlled in vitro environment before embarking on the
highly complex in vivo situation.
A number of authors have focussed speciﬁcally on modelling
the release of drug from DESs, electing to put to one side the range
of complexities that are observed in the in vivo situation (including
ﬂowing blood, pulsatility, wound healing, proliferation, migration
of cells and complex uptake/binding). This approach has proven
to be useful in helping to address the question of what mecha-
nism(s) are behind the release of drug from a number of stent
systems and also in allowing estimates of parameter values
(e.g. diffusion coefﬁcients) to be made. Of course, modelling drug
release is not an area of research exclusive to DESs. In fact,
scientists have been devising models which describe the release
of drug from tablet formulations and drug delivery devices for dec-
ades. It is therefore not a surprise that the early models of drug
release from DESs incorporated well-established ideas from other
applications.
2.1. Drug release from non-erodible polymer coated stents
Drug release from DESs comprising non-erodible polymers has
been modelled as a diffusion dominated process (see for example
[6–8]), with the drug concentration in the polymer Cp satisfying
a diffusion equation with drug diffusion coefﬁcient Dp. The geom-
etry can be assumed to be that of a thin ﬁlm of thickness Lp with no
edge effects so that the modelling may be simpliﬁed to one
dimension:
@Cp
@t
ðx; tÞ ¼ Dp @
2Cp
@x2
ðx; tÞ; x 2 ð0; LpÞ; t > 0: ð1Þ
In this one-dimensional setting, a zero-ﬂux condition is normally
imposed since the stent is impermeable and the initial drug concen-
tration is taken to be uniform. McGinty et al. [9] impose perfect sink
conditions (Cp ¼ 0) where the drug meets the release medium
(these are conditions which can be controlled in the in vitro exper-
iment). Zhao et al. [10] presented a similar model, albeit in a cylin-
drical geometry, when describing the experimental drug release of
everolimus from a Dynalink-E polymer coated stent:
@Cp
@t
ðr; tÞ ¼ Dp @
2Cp
@r2
ðr; tÞ þ 1
r
@Cp
@r
ðr; tÞ
 !
; r 2 ða; bÞ; t > 0; ð2Þ
where, here, a is the inner radius (the boundary with the metal
stent), b is the outer radius (the boundary with the release medium)
and the same initial and boundary conditions as in the McGinty
et al. model are supposed. Each of these models admits an analytical
solution and has shown favourable results when compared with
in vitro experimental data. McGinty et al. and Zhao et al. provide
the respective solutions for the cumulative fraction of drug released
(Mfrac):
MfracðtÞ ¼ 1 8p2
X1
n¼1
1
2n 1ð Þ2
exp
 2n 1ð Þ2p2Dpt
4L2p
( )
; ð3Þ
MfracðtÞ ¼ 1 42aþ Lp
 
Lp
X1
n¼1
exp Dpa2nt
 
1 J20ðbanÞ=J21ðaanÞ
; ð4Þ
where an is the nth positive root of J1ðaanÞY0ðbanÞ
Y1ðaanÞJ0ðanÞ ¼ 0 with J0ðxÞ and J1ðxÞ Bessel functions of the ﬁrst
kind of orders 0 and 1, and Y0ðxÞ and Y1ðxÞ are Bessel functions of
the second kind of orders 0 and 1, respectively. In each model the
diffusion coefﬁcient is assumed to be constant. McGinty et al.demonstrated that in vitro sirolimus release from the Cypher stent
was well described by (3) indicating that diffusion was the
dominant release mechanism. They estimated the diffusion coefﬁ-
cient to be of Oð1017Þm2 s1 via a best ﬁtting process. Zhao et al.
also conﬁrmed diffusion dominated release from the Dynalink stent
and they found that their model solution could be ﬁtted to both
in vitro and in vivo release data simply by varying the coating
diffusion coefﬁcient. But it is not clear why the coating diffusion
coefﬁcient should be different in the two cases. They found that
for the in vivo release a diffusion coefﬁcient approximately ten
times smaller than the in vitro release was required (Oð1017Þ and
Oð1016Þm2 s1, respectively).
Hossainy and Prabhu [11], in an attempt to predict the release
of everolimus from a biodurable ﬂuoropolymer-based DES coating,
also adopted a diffusion based approach, but they assumed a bimo-
dal lumped-parameter model. Differently from the models of
McGinty et al. and Zhao et al. the assumption is made that the dis-
persed drug phase contributes to two discrete modes of drug trans-
port through the coating. The ﬁrst mode is the fast one in which
drug is released from a highly percolated structure and the second
mode is the slow one where drug is released from a non-percolated
polymer encapsulated phase. Although Robin-type boundary
conditions are proposed, the parameter values chosen by the
authors are such that sink conditions are supposed. The result is
Eq. (1) for each mode of transport, with the same zero ﬂux and inﬁ-
nite sink boundary conditions. The difference between the two
modes is captured by a different diffusion coefﬁcient. A further
parameter, a, which deﬁnes the ratio of drug in the ﬁrst mode to
the total drug, is deﬁned. The authors numerically obtain estimates
of the diffusion coefﬁcients and a by way of a numerical error min-
imisation process. They utilise in vivo experimental data from a
porcine animal study. Good agreement between the model and
experiments is observed with the mode 1 and 2 diffusion coefﬁ-
cients predicted to be of order Oð1013Þ and Oð1014Þm2 s1,
respectively. The parameter a is calculated to be 0.22 and is found
to reduce as the initial drug density is increased, i.e. as more drug is
loaded initially, a larger fraction of drug exists in the non-
percolated phase. The authors also attempt to predict the release
of a combination of drugs from a stent coating. They use the same
minimisation technique, this time requiring to ﬁnd six ﬁtting
parameters. The authors conclude that the validation of their
model with experimental data conﬁrms the mechanistic behaviour
of the mass transport phenomena within the coating and their
assumption of a biphasic state of drug phase within the coating.
Interestingly, the authors also show a plot which compares their
model prediction with Cypher release data and claim that the
model can be used to predict drug release from the Cypher stent.
However, they do not specify the values of diffusion coefﬁcients
and a they use to generate their plots. Given that these values
are unlikely to be known a priori it seems that a numerical
algorithm approach has been adopted to ﬁnd the parameter values
which best ﬁt the data. It is interesting that the models of Hossainy
et al. and McGinty et al. have both demonstrated good agreement
with Cypher release proﬁles, albeit McGinty et al. compared with
in vitro data, while Hossainy compared with in vivo data. Thus a
warning must be issued: a good ﬁt to experimental data does not
necessarily conﬁrm that the model is correct. With certain param-
eter values, it may be possible to show that a set of experimental
data is ﬁtted well by several different models.
While not focussing speciﬁcally on DESs, Siepmann and Siep-
mann [12] in their review onmodelling of diffusion controlled drug
delivery provide a series of analytical solutions for drug release from
reservoir andmonolithic drug delivery systems, some of whichmay
be applied to DESs under certain assumptions. Many of their solu-
tions are early or late time approximations, and in some cases steady
state solutions. The reader is referred to [12] for full details.
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stents seems to be well described by diffusion alone, this is not
the case for all DESs. Realising that the release mechanism may
not be as simple as pure diffusion, Tzafriri et al. [2] chose to write
down a two-part equation to describe drug release from the
Cypher and NEVO stents and, using a best ﬁtting process, found
the values of the parameters of the model. Their approach was of
interest to industry since it aimed to compare and contrast the
release kinetics of two different types of stent platforms, by way
of experimentation coupled with modelling. With similarity to
Hossainy et al., their equation assumes that these stents contain
two pools of dispersed drug, one that is surface-connected and
elutes through a percolating network of drug ﬁlled pores, and
another that is embedded within the matrix and diffuses more
slowly through the percolating polymer phase. Thus they utilised
the following equation for the mass of drug released from the
Cypher and NEVO stents:
Mstentð0Þ MstentðtÞ ¼ Mf0 1 eKf0 t
 
þ Qsus
ﬃﬃ
t
p
; ð5Þ
where Mstentð0Þ; Mf0 ; Kf0 and Qsus denote, respectively, the initial
load of drug, the initial pool of ﬁrst order eluting drug, rate constant
and Higuchi rate constant. This equation, however, is empirically-
based and does not satisfy mass conservation principles: the mass
of drug released eventually tends to inﬁnity as time increases. As
a result, while their data is well-ﬁtted to this equation for this set
of experiments, it is unlikely that their model may be used in a pre-
dictive capacity. It is noteworthy that Tzafriri et al. found that the
Nevo release data ﬁt (5) best when Mf0 ¼ 0, suggesting that for this
stent there is only one mode of elution.
Building on the idea that drug coated on stents may exist in two
distinct forms (dissolved and undissolved), McGinty et al. [9]
provided a series of diffusion–dissolution based models which all
admitted analytical solutions. Their intention is that these
analytical solutions, when used in conjunction with appropriate
experimental data, may be easily utilised by researchers or indus-
trialists to help clarify the release mechanism (s) and thus aid in
the development of DESs. The ﬁrst model they present couples dif-
fusion with instantaneous dissolution and is based on the early
works of Higuchi [13]. The model assumes that drug is initially
present at a concentration (C0) exceeding solubility (Cs) in the
coating and that the drug is dissolved instantly on a moving front
which penetrates into the coating. They provide the solution
(under sink conditions) in two parts. The ﬁrst part describes the
mass of drug released up until the time (tH) where the drug
concentration throughout the coating falls below solubility. The
second part describes the duration of the release:
MfracðtÞ ¼
ﬃﬃ
t
p
LpC
0 h C
0  Cs
 
þ
2
ﬃﬃﬃﬃﬃﬃ
Dp
p
Cs 1 exp  h24Dp
n o 
ﬃﬃﬃ
p
p
erf h
2
ﬃﬃﬃﬃ
Dp
p
	 

8>><
>:
9>>=
>;; t < t
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ð6Þ
MfracðtÞ ¼ 1
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2
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Dp
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X1
n¼1
exp
Dpð2n1Þ2p2
4Lp
t
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R erf
ð2n1ÞipDptHþL2p
2Lp
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DptH
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2n1ð Þ2
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ð7Þ
where tH ¼ ðLp=hÞ2 and h is found by solving
2
ﬃﬃﬃﬃﬃﬃ
Dp
p
r
Cs
C0  Cs
¼ herf h
2
ﬃﬃﬃﬃﬃﬃ
Dp
p
 !
exp
h2
4Dp
( )
: ð8ÞThe error function, erf, is a standard mathematical function and is
discussed in, for example, Crank [14]. McGinty et al. also provide
an analytical solution for the case of release governed by diffusion
and dissolution involving a linear ﬁrst order reaction. The drug is
assumed to exist in two forms: dissolved (or free) (Cf ) and undis-
solved (or bound) (Cb). The drug can dissolve into the free form
via the forward reaction rate K1 and then transform back into bound
drug via the backward reaction rate K2:
@Cf
@t
ðx;tÞ¼DP @
2Cf
@x2
ðx;tÞþK1Cbðx;tÞK2Cf ðx;tÞ; 0< x< Lp; t>0;
ð9Þ
@Cb
@t
ðx;tÞ¼K1Cbðx;tÞþK2Cf ðx;tÞ 0< x< Lp; t>0: ð10Þ
In deriving their solution they assume that all of the drug is initially
in undissolved form and they impose a zero-ﬂux condition at the
impermeable stent and a sink condition at the boundary with the
release medium. The solution is
MfracðtÞ¼1exp K1tf gþ2K2K1Dp
L2p

X2
j¼1
X1
n¼1
sjnþK1
 2 exp sjn tf gexp K1tf g
K1þsjn
þexp ðK2þK1Þtf gexp K1tf gK2
	 

sjn s
2
jn
þ2K1sjnþK1ðK2þK1Þ
 
K2þK1þsjn
 
þ2K1Dp
L2p
X2
j¼1
X1
n¼1
sjnþK1
 2 exp sjn t exp ðK2þK1Þtf g 
sjn s
2
jn
þ2K1sjnþK1ðK2þK1Þ
 
K2þK1þsjn
 
where
2s1n ¼  K2 þ K1 þ
Dp
4L2p
p2 2n 1ð Þ2
 !
þ
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K2 þ K1 þ Dp
4L2p
p2 2n 1ð Þ2
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 K1Dp
L2p
p2 2n 1ð Þ2
vuut2s2n ¼  K2 þ K1 þ
Dp
4L2p
p2 2n 1ð Þ2
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
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K2 þ K1 þ Dp
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 !2
 K1Dp
L2p
p2 2n 1ð Þ2
vuut :
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They show that by taking the limit as K2 ! 0, the equivalent expres-
sion for a non-reversible reaction can be derived:
MfracðtÞ ¼ 1 exp K1tf g
 8K1
p2
X1
n¼1
exp Dp
4L2p
ð2n 1Þ2p2t
 
 exp K1tf g
ð2n 1Þ2 K1  Dp4L2p ð2n 1Þ
2p2
	 
 : ð12Þ
They argue that, when compared with appropriate experimental
data, the solutions can readily conﬁrm the release mechanism(s)
and further, allow estimation of the various parameters of the sys-
tem via the inverse problem. Pontrelli et al. [15] have adopted a
similar approach to modelling drug release from the coating. They
too assume that drug within the coating exists in two phases. They
neglect diffusion within the solid phase so that their equations are
essentially (9) and (10) albeit with their parameters deﬁned differ-
ently to include the effects of partitioning of drug between the two
phases and the porosity of the coating.
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Up until now we have focussed on models which describe the
drug release from ﬁrst and second generation DESs. Newer genera-
tion DESs which have focussed on biodegradable polymers and
polymer-freemodiﬁed surface designs are likely to havemore com-
plicatedmechanisms of release, and so it is of industrial relevance to
consider these types of stents in their own right. In the case of stents
with biodegradable polymeric coatings, the drug release may
involve diffusion, erosion and possibly dissolution and/or swelling
[16,17]. However, in the case of polymer-free stents, it is less clear
how the sustained release is obtained and how this may be mod-
elled. Because of the complexities involved in systems which
degrade as they release drug, amodelwhich is shown to be accurate
for one systemmay be useless for another. Nevertheless, we discuss
here some of the published models in the literature, but invite the
reader to refer to the speciﬁc articles for full details. Before doing
so, it is useful to clarify what is meant by some of the common pro-
cesses which appear in these models: hydration, degradation and
erosion. Hydration is simply the process of combining with water.
Degradation is a chain scission process which involves the breaking
of polymeric chains by free radicals. On the other hand, erosion is
material loss froma systemand can be either surface erosion or bulk
erosion. With surface erosion, water intrusion into the polymer is
slow compared with the rate of degradation, thus the polymer is
‘eaten away’ from the outside to the inside. With bulk erosion, the
rate of degradation is slow compared with the rate of water uptake
and so the entire system is rapidly hydrated and degradation occurs
throughout the whole material equally.
Prabhu and Hossainy [18] focused speciﬁcally on the degrada-
tion and release of everolimus from a polylactic (PLA) stent coating
and validated their compartmentalised model using in vitro data.
The model considers two non-linear reactions: the hydrolysis (by
water intrusion) of PLA to produce oligomers and lactic acid and
the hydrolysis of oligomers to produce lactic acid. Five reaction dif-
fusion equations are presented to describe the temporal and spatial
evolution of the concentrations of water, PLA, oligomers, lactic acid
and everolimus. The model equations were solved using an
iterative ﬁnite difference approach which updates estimates of
the various parameters via comparison with the experimental
data. They indicate that autocatalysis (i.e. a reaction where the
reaction product itself is the catalyst of the reaction) is important
and cannot be ignored. While not directly focussing on DESs, Siep-
mann and Gopferich [19] provided a review of the mathematical
modelling of bioerodible polymeric drug delivery devices. They
consider only systems where the drugs are physically immobilized
within a water insoluble polymeric matrix. They stress that accu-
rate physiochemical characterisation of the investigated system
is an absolute pre-requisite for the appropriate mathematical mod-
elling of the device, and as such they detail techniques to experi-
mentally characterise degradation and erosion. These can help
identify whether the erosion is surface or bulk and assist in clarify-
ing the time-dependence of the diffusion coefﬁcients. Among the
models presented are those of Heller and Baker [20] which
involves modiﬁcation of the Higuchi equation to include a time-
dependent permeability as a result of bulk erosion, the model of
Lee [21] which lends itself to an approximate analytical solution
for drug release from thin eroding ﬁlms and the models of Joshi
and Himmelstein [22,23] which accounts for acid producing spe-
cies that accelerate matrix hydrolysis. The authors comment that
modelling efforts should try to take into account the in vivo
conditions since, for example, cellular tissue reactions can affect
the degradation process. Again, not referring speciﬁcally to DESs,
Rothstein et al. [24] present a uniﬁed model for the prediction of
controlled release from surface and bulk eroding polymer matrices
which also accounts for the transition from surface eroding to bulkeroding behaviour during the course of degradation. Soares and
Zunino [25] introduced a mixture model for water uptake, degrada-
tion, erosion and drug release from polydisperse polymeric net-
works. Each constituent of the model represents chains of an
average size. A multiscale description of degradation and erosion
is proposed, combining the molecular description of scission with
Fick’s macroscopic laws of diffusion. The approach adopted here
describes degradation by means of the time evolution of weight
fractions of polymeric constituents of average degree of polymeri-
sation. They argue that the key advantage of their model is the fact
that polymer degradation is described as an individual chemical
reaction. Rossi et al. [26] modelled a bioresorbable DES based on
detailed constitutive equations and taking into account the main
physical and chemical mechanisms involved in coating degrada-
tion, drug release and restenosis inhibition. Their results were ver-
iﬁed against selected in vitro and in vivo data available in the
literature. Formaggia et al. [27] considered a two dimensional
dissolution–diffusion model which also included surface erosion.
Similarly to McGinty et al. [9], they too realised that as a result of
the industrial manufacturing coating process, the drug may exist
in the coating in a form which needs to dissolve before it can
diffuse. They consider the drug in polymer as two separate phases:
a dissolved phase and a solid phase with concentrations Cf and Cb,
respectively. Only dissolved drug is permitted to diffuse. Thus they
include a source term in the diffusion equation to account for the
solid phase dissolution. The dissolution term is non-linear and is
based on a reformulation of the empirical Noyes–Whitney equation
[28] with the dissolution coefﬁcient, K1, possibly space and time
dependent. The resulting equations in the polymer coating are
@Cf
@t
r  DprCf
  ¼ K1C2=3b Cs  Cf ; ð13Þ
@Cb
@t
¼ K1C2=3b Cs  Cf
 
: ð14Þ3. Modelling drug transport through the arterial wall
Modelling the release of drug from arterial stents is only one
part of the story. What happens to the drug after it is released
in vivo is of more clinical interest and certainly more difﬁcult to
model. Clinicians advise that a uniform drug concentration should
be attained across the arterial wall, and the concentration should
be maintained within some therapeutic window. Thus an under-
standing of the structure and components of the arterial wall is
crucial. The arterial wall is a porous heterogeneous structure, con-
sisting of three distinct layers (see Fig. 2). Closest to the lumen is
the intima, followed by the media and ﬁnally the adventitia [29].
The intima consists of the sub-endothelial space and the endothe-
lial layer of cells, known as the endothelium. This layer is crucial to
the control of the normal function of the artery, through its medi-
ation of relaxation and contraction and via its control of smooth
muscle cell proliferation within the underlying media layer. The
internal elastic lamina forms the outermost part of the intima.
The media region comprises smooth muscle cells, collagen and
elastin. Finally, the outermost layer of the arterial wall is the
adventitia. The adventitia tethers the artery to perivascular tissue,
and contains cells known as ﬁbroblasts as well as a network of
small blood vessels, called vasa vasorum, which act as a blood sup-
ply to the adventitia and provide a clearance mechanism for drugs
released into the artery wall.
3.1. The advection–diffusion–reaction equation
The processes that govern mass transport through the arterial
wall are diffusion, convection and binding (reaction). If the arterial
Fig. 2. The structure of the arterial wall.
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by an advection–diffusion–reaction equation of the form:
@C
@t
þ v  rC ¼ Dr2C  R; ð15Þ
where, here, C is the concentration of drug in the wall, v is the trans-
mural convection (as a result of the pressure difference across the
wall), D is the diffusivity tensor and R represents the binding ‘reac-
tion’, whichmay take several forms. For a derivation of the transport
equation the reader is referred to, for example, de Monte et al. [30].
Actually, we require an equation of the form (15) for each layer of
the arterial wall since the material properties are different in each
layer. In particular, the different composition of each layer results
in differing porosities, diffusion coefﬁcients and binding properties.
There is evidence that within each layer, anisotropy may be impor-
tant. For example, diffusionwithin the tissue has been reported to be
anisotropic [31,32] with the diffusion coefﬁcient in the radial direc-
tion possibly as much as 100 or 1000 times less than in the circum-
ferential and axial directions. The diffusion coefﬁcients in the
following models incorporate the effects of porosity and tortuosity
and are sometimes referred to as ‘effective’ diffusion coefﬁcients.
The ﬁrst mathematical treatment of arterial drug transport
seems to have been by Zunino who built on the earlier experimen-
tal works of Creel et al. [33], Hwang et al. [34], Lovich et al. [35],
Hwang and Edelman [36] and Lovich and Edelman [37]. The pur-
pose of Zunino’s work was to show how mathematical models
and numerical simulations can help to identify the physical prop-
erties of the stent coating in order to ensure a desired drug release
rate. In his model, Zunino assumed the transport was via convec-
tion and diffusion with instantaneous reaction. Volume averaged
drug concentrations, C, deﬁned as the amount of drug in the ﬂuid
phase plus the amount of drug bound with the tissue, divided by
the considered control volume, were utilised. Zunino related the
ﬂuid phase drug concentration, Cf , to the concentration of drug
in a control volume, via Cf ¼ C=ðK/Þwhere / represents the poros-
ity of the medium and K is the partition coefﬁcient which deﬁnes
the equilibrium ratio of bound drug within the tissue with respect
to drug dissolved in the ﬂuid. He proposed the following equation
in two dimensions:
@C
@t
þr  DrC þ cu
K/
C
	 

¼ 0; ð16Þwhere 0 < c < 1 accounts for possible frictional effects between
drug molecules and the pores. Here u is deﬁned as the ﬁltration
velocity. Zunino’s most important ﬁnding was that drug retention
strictly depends on the properties of the drug inside the wall and
is not inﬂuenced by the characteristics of the carrier.
3.2. Modelling drug binding in arterial tissue
While the convective and diffusive element of the drug
transport is well established, the issue of drug binding is more
controversial. Some authors have assumed equilibrium models
[6,38,39], while others have considered simple loss terms
[7,8,40,41]. More recently, non-linear saturable binding models
have been utilised [2,42–44].
3.2.1. Models involving linear reaction terms
The simplest form of reaction is a loss term which accounts for
consumption of drug in the system (for example, to cells or
through vasa vasorum blood vessels). If drug is lost from the system
in proportion to some parameter, say b, then the reaction termmay
be written as:
R ¼ bC: ð17Þ
Pontrelli and de Monte [40] proposed a model which incorporated
(15) along with binding of the type (17). Their most sophisticated
model [41] has the beneﬁt of being multi-layered, although only
one-dimension is considered. In each layer, the drug transport is
described by
/
@Ci
@t
ðx; tÞ þ 2ci
@Ci
@x
ðx; tÞ ¼ Di @
2Ci
@x2
ðx; tÞ  biCiðx; tÞ; ð18Þ
where the subscript i indicates the ith layer, 2ci represents a con-
stant characteristic convection parameter and Di represents the
effective diffusion coefﬁcient. Pontrelli and de Monte’s model has
the advantage of admitting an analytical solution.
McGinty et al. [6] utilised a more sophisticated reaction model
based on the idea that the drug in the tissue exists in two phases:
an extracellular ﬂuid phase and a solid cellular phase. If in equilib-
rium the concentration of drug in the bound solid phase (Cb) is
some constant, say K, times the concentration in the extracellular
ﬂuid phase (C), then we may have the following reaction term:
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@t
¼ aðC  Cb=KÞ; ð19Þ
where a is a rate constant. Absorbing the porosity terms into a for-
ward reaction uptake rate kf and backwards reaction rate kr , the
McGinty model becomes
@Cb
@t
¼ kf C  krCb; ð20Þ
which is identical to the form of reaction considered by Horner et al.
[38] and Abraham et al. [39]. Horner et al. conclude in their analysis
that a single species drug delivery model cannot accurately predict
the distribution of bound drug and so a two-species approach that
includes reversible binding is essential.
3.2.2. Models involving non-linear reaction terms
While it is generally appreciated that a reversible reaction is
required to describe binding, the form need not be linear. In partic-
ular, if we consider the drug binding process as a ligand binding to
a receptor to form a complex then we can utilise some ideas from
molecular cell biology. Consider the following equilibrium binding
for a reversible reaction between a receptor (r) and ligand (l) to
form a receptor/ligand complex (c) [45]:
lþ r 
kf
kr
c;
where, here, kf and kr are termed the association and dissociation
rate constants, respectively. Assuming that each ligand binds only
with one binding site (or receptor), Lauffenburger and Linderman
present the following ﬁrst order reversible saturable equation
describing the time rate of change of concentration of the complex:
dc
dt
¼ kf rl krc; ð21Þ
where here kf characterises the velocity of the second-order inter-
action between the receptor and ligand while kr characterises the
velocity of the ﬁrst-order breakdown of the receptor/ligand com-
plex. It will be convenient to refer to receptors as unoccupied bind-
ing sites and receptor/ligand complexes as occupied binding sites. It
will also be useful to deﬁne a binding site conservation condition:
bðtÞ þ aðtÞ ¼ bmax; ð22Þ
which states that at any time the number of occupied binding sites,
b, plus the number of unoccupied binding sites, a, is equal to the
local density of binding sites, bmax.
Sakharov et al. [42] seems to be the ﬁrst group to have applied
this type of binding model within a DES setting. They provide the
following binding equation which describes the rate of change of
concentration of unoccupied binding sites:
dCa
dt
¼ kf CCa þ kr bmax  Caf g; ð23Þ
where, here, C and Ca denote the concentrations of free drug and
unoccupied binding sites, respectively. Tzafriri et al. [43] provide
an alternative equation in terms of the rate of change of occupied
binding sites.
dCb
dt
¼ kf C bmax  Cbf g  krCb; ð24Þ
where Cb is the concentration of occupied binding sites (bound
drug). It is straightforward to show that (24) is equivalent to (23)
by substituting (22) into (23). This type of binding model has also
been adopted by other authors [44]. It is well established that in
addition to binding to speciﬁc receptors, there is also the occurrence
of relatively weak non-speciﬁc binding caused by association of
drug with membrane constituents or by trapping of drug in the
extracellular medium [45]. While it is believed that only thereceptor (speciﬁc) binding is linked to the desired biological effect,
binding to non-speciﬁc sites will nevertheless, have an impact on
drug distribution. Taking this into account, Tzafriri et al. [2] in their
most recent work include two equations for drug binding in arterial
tissue: one for speciﬁc binding to receptors (24) and another for
non-speciﬁc binding to general extracellular matrix (ECM) sites:
dCbns
dt
¼ kfnsC bmaxns  Cbnsf g  krnsCbns ; ð25Þ
where here the subscript ns indicates non-speciﬁc. While determin-
ing which type of binding model is most appropriate is not within
the remit of this review, it is worth stating that Tzafriri et al. [43]
found that while a non-saturable linear model of the type (20)
agrees with a saturable model of the type (24) in simulating the
predicted arterial distribution of heparin, this is not the case for
more lipophillic drugs like paclitaxel and sirolimus. They argue that
the nonsaturable binding model signiﬁcantly underestimates the
depth of paclitaxel and sirolimus penetration while overestimating
the total arterial deposition. However, no experimental results are
presented to compare with the simulations. On the other hand,
Zhu et al. [46] considered a compartmental model of the type (20)
to describe uptake of drug into SMCs and demonstrated good
agreement with experiments. It is certainly true that the drug will
bind to binding sites in the tissue and on/in cells [2,47,48] although
the strength of the afﬁnity will likely vary substantially with the
particular drug under consideration. Furthermore, it is not clear
how the density of the binding sites may be easily measured
in vivo. Thus it may be that this binding model is speciﬁc to a par-
ticular class of drugs and not suitable for more general compounds.
A greater understanding of the binding process would undoubtedly
assist with model development.
4. Modelling the coupled stent-wall system
So far we have reviewed the modelling of drug release from
DESs and drug transport through arterial tissue, both of which
are important problems in their own right. In reality, of course,
the stent and arterial wall are a coupled system. Thus, to accurately
model the in vivo situation we are obliged to consider the interac-
tion between the stent and the tissue. The coupled problem has
received much attention in the literature, with most of the models
necessarily requiring to be solved numerically due to the complex-
ity of the problem. One exception is the model due to Pontrelli and
de Monte [40] who consider diffusion based drug release from a
non-erodible polymer-coated stent (Eq. (1)) coupled with a con-
vection–diffusion equation in the arterial wall which also accounts
for drug consumption via a linear reaction (Eq. (18)). They assume
that where the polymer rests against the bare metal of the stent
there is zero ﬂux and that the initial concentration within the
polymer is some constant C0. At the polymer/tissue interface the
total ﬂux is assumed to be continuous, and a top-coat on the
polymer is allowed for:
Dp
@Cp
@x
¼ D @C
@x
 2cC; ð26Þ
Dp @Cp
@x
¼ P Cp
Kp/p
 C
K/
 !
; ð27Þ
where, here, P denotes a parameter with units m s1 and the sub-
script p denotes parameters associated with the polymer. At the
perivascular end of the tissue they assume that C ¼ 0. The signiﬁ-
cance of Pontrelli and de Monte’s work is that they were able to
obtain an analytical solution for the drug concentration in the
polymer and the media tissue region (through separation of
variables), allowing drug concentrations to be readily computed.
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advection lowers the observed wall concentration curves due to
the convective velocity sweeping away drug from the wall and that
at intermediate and later times, a more uniform concentration is
guaranteed. In addition they found that increasing the drug
consumption rate diminishes the concentrations but preserves the
proﬁle shapes. The drug diffusivity in the wall was shown to greatly
inﬂuence the residence time of the drug. The relevance of this ﬁnd-
ing is that drugs which exhibit a smaller diffusivity in the arterial
wall will be retained longer. Their work has been extended to
multi-layers [41].
While the models of Pontrelli and de Monte are an important
contribution to the ﬁeld, they are unable to model the spatial
and temporal concentration of bound drug. Indeed, the drugs used
in DESs are usually targeted to bind to speciﬁc receptors on/in
SMCs. One of the ﬁrst stent/tissue models which encompassed
convection, diffusion and uptake into SMCs within the porous
media was presented by McGinty et al. [6]:
@Cp
@t
ðx; tÞ ¼ Dp @
2Cp
@x2
ðx; tÞ; x 2 ð0; LpÞ; t > 0; ð28Þ
/
@C
@t
þ v @C
@x
¼ D @
2C
@x2
 a C  Cb
K
	 

; x 2 ðLp; Lp þ LÞ; t > 0; ð29Þ
ð1 /Þ @Cb
@t
¼ a C  Cb
K
	 

; x 2 ðLp; Lp þ LÞ; t > 0; ð30Þ
where C and Cb denote the volume averaged concentration of drug
in the extracellular and cellular regions, respectively [6]. The
parameters /; v; D; a; K and L denote the porosity, magnitude of
effective transmural convection, effective drug diffusion coefﬁcient
in the media, drug uptake rate constant, partition coefﬁcient and
thickness of the media region. Eq. (30) expresses the rate of uptake
of drug by the cells: it is initially proportional to the free drug C but
that proportionality diminishes with increasing Cb until the carry-
ing capacity (or partition coefﬁcient) of the drug is reached at which
point the uptake becomes zero. This system of equations allows for
an exchange of drug between the extracellular phase and the cells
which is dependent on the concentration in the extracellular phase.
The boundary conditions they adopted at the interface between the
polymer coating and the arterial tissue were continuity of the
relative ﬂuxes (Eq. (26) with v replacing 2c) and continuity of ﬂuid
drug concentration. They assumed that the ﬂux of drug out of the
media was proportional (via some parameter d) to the concentra-
tion at the interface between the media and adventitia to provide
the ﬁnal boundary condition:
D @C
@x
þ vC ¼ dC: ð31Þ
Their model was also extended to include the adventitia region
(where ﬁbroblast cells were modelled in a similar way to SMCs), a
topcoat of polymer to slow the release of the drug, and one of the
ﬁrst models of atherosclerotic plaque (modelled using an
equilibrium model in the same way as SMCs uptake).
McGinty et al. simulated the problem using a ﬁnite difference
scheme and conducted a thorough sensitivity analysis which
allowed them to infer the importance of the parameters in their
model. They found that the results were particularly sensitive to
ﬂuctuations in the magnitude of the transmural velocity, and to
changes in the drug uptake rate and partition coefﬁcient. Small
changes in these parameters were found to result in a large large
variation in clinically signiﬁcant indicators such as uniformity of
the concentration proﬁle, maximum cellular drug concentrations
and therapeutic period (the time period over which the cells are
exposed to drug levels within a clinically relevant therapeutic
window). The signiﬁcance of this ﬁnding is that it is important
that reliable measurements/estimates of these parameters areobtained. In line with the ﬁndings of Pontrelli and de Monte, they
found that as the magnitude of the transmural velocity was
increased, the wall concentration proﬁle became more uniform
but they also noted that the therapeutic period was signiﬁcantly
reduced while the maximum cellular concentration attained was
increased. Increasing the drug uptake rate can reduce the thera-
peutic period, while increasing the partition coefﬁcient can signif-
icantly increase the therapeutic period. Their simple model of
plaque suggested that the plaque could act as a reservoir for the
drug, ensuring that patients with a higher degree of atherosclerosis
may receive therapeutic levels of drug for longer than those with a
lesser degree of plaque. This ﬁnding is in contrast to an experimen-
tal study in the literature [49] where it was concluded that drug
concentration was inversely correlated to lipid concentrations.
The McGinty et al. model did, however, neglect the intimal region
of the arterial wall and the endothelium layer of cells (as indeed
have several other authors). Their justiﬁcation for this is that the
endothelium is severely damaged when a stent is inserted and in
some cases is completely removed; and indeed the properties of
the intima may not be too different from those in the media. In a
subsequent paper, McGinty et al. [50] combined their earlier work
[6] with that of Pontrelli and de Monte [40] to obtain an analytical
solution for the drug concentration both in the target cells (Cb) and
the interstitial region of the tissue (C) in terms of the drug release
concentration at the interface between the polymer and the tissue.
They showed that when the polymer region and the tissue region
are considered as a coupled system, under certain assumptions,
the drug release concentration satisﬁes a Volterra integral equation
which must be solved numerically in general. The drug concentra-
tions, both in the cellular and extracellular regions, are then
determined from the solution of this integral equation and then
used in deriving the mass of bound drug in the cells.
Building upon their earlier works, Pontrelli et al. [15] presented
a semi-analytical expression for the drug concentration and mass
in each layer of the arterial wall for the case where the drug must
dissolve in the polymer before it can diffuse. The equations for drug
transport through the tissue layers were identical to their earlier
models [40] but now the equations for the drug in the coating were
similar to (9) and (10):
@Cf
@t
ðx; tÞ ¼ DP @
2Cf
@x2
ðx; tÞ þ Kp/p
tf
Cb  CfKp/p
 !
; ð32Þ
@Cb
@t
ðx; tÞ ¼ qf
tf
Cb  CKp/p
 !
: ð33Þ
Here tf is a function of the physio-chemical properties of the sub-
stance and of the microstructure of the porous material and qf is
the ratio of non-solid volume to solid volume. In their analysis, Pon-
trelli et al. exploit a perturbation solution method (noting that the
coating thickness is much less than the penetration distance) as
an alternative to numerical integration. They conclude that the
solid–liquid mass transfer time can have a signiﬁcant inﬂuence on
the time taken for drug to be released from the coating as well as
the on the drug mass distribution in the wall.
The coupled models discussed so far, all being one-dimensional,
have allowed for analytical or semi-analytical solutions due to the
particular simpliﬁcations that were made. However, in general,
analytical solutions are extremely difﬁcult to obtain, especially
when two or three dimensions are considered. Zunino [8], in his
early model, considered a two-dimensional geometry and solved
the diffusion equation in two dimensions coupled with an
advection diffusion Eq. (16) for the drug concentration in the arte-
rial wall. Zunino obtained the velocity ﬁeld by consideration of
Darcy’s Law and applied a ﬁnite element approach to solving the
resulting equations. Zunino was able to show that a signiﬁcant
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and 60% for paclitaxel) and this is related to the binding and diffu-
sion properties of drug in the tissue. This has implications for stent
manufacturers when considering the type of drug to include on
their stent. Due to the zero-ﬂux conditions imposed by McGinty
et al. [6] and Pontrelli and de Monte [7,40] in their one-dimen-
sional setting, this is a feature that they neglect and may well lead
to over-prediction of drug concentrations in the arterial wall. Two-
dimensional models in simpliﬁed geometries were also computed
by [32,51], among others.
A number of three-dimensional models have also been devised.
Moving to three dimensions opens up the possibility of considering
more realistic geometries than the simpliﬁed cases considered in
the lower dimensional models. However, these models require to
be solved numerically and often make a number of assumptions
to facilitate quick computation or to reduce the complexity of
the numerical code. Weiler et al. [52] provided a broad generaliza-
tion of the works of [53–55]; a three-dimensional model of drug
transport in the lumen and the arterial wall. Laminar steady ﬂow
was assumed in the lumen and the steady diffusion equation (no
convection or reaction) in the arterial wall. Through numerical
simulation using commercial ﬁnite element software, they found
that the highest rates of mass transfer occurred at the forward por-
tion of the stent and the rate of drug delivery to the lumen was
greater than that to the tissue. The implication is that not all of
the drug on the stent will actually reach the tissue. Indeed many
commercially available stents now only coat drug abluminally.
While not the focus of this review, a number of studies have con-
sidered the interaction of blood ﬂow and drug release. Zunino
et al. [56] found that a signiﬁcant fraction of the drug that is
released into the blood ﬂow resides into the recirculation down-
stream of the struts, where it can be absorbed into the arterial wall.
They also found that the interaction between the blood ﬂow and
the struts can result in very complex ﬂow patterns [57]. Borghi
et al. [58] also considered the interaction with ﬂow in their model,
which also included a nonlinear model of binding in the tissue as
well as a degradable polymer matrix. The reader is referred to
these articles for further details.
Horner et al. [38] appear to be one of the ﬁrst authors to provide
a three-dimensional reaction–diffusion–convection model in a
realistic geometry. They stress the importance of considering two
phases of the drug (bound and unbound) and use a ﬁrst order reac-
tion kinetics model to describe the transfer of drug between the
two phases. They utilise ABAQUS (commercial ﬁnite element anal-
ysis software) to obtain a realistic geometry of a deformed stent
and vessel wall and then employ FLUENT (commercial software
with ﬂow modelling capabilities) to solve their transport equa-
tions. Their three-dimensional setting allows for the consideration
of anisotropic diffusion in the arterial wall. They do, however,
make three signiﬁcant simpliﬁcations. Firstly, they model the arte-
rial wall as a linear homogeneous solid and do not distinguish
between the intima, media and adventitia. Secondly, despite calcu-
lating the transmural velocity ﬁeld, they assume this is ﬁxed when
solving the transport equations. Perhaps the most unrealistic
assumption is that the drug concentration on the stent remains
constant and does not deplete. They ﬁnd that deposition patterns
tend to follow the pattern of the stent struts and that the drug is
able to penetrate deep into the arterial wall. The pattern of bound
drug becomes less uniform as the Peclet number is increased,
eventually becoming restricted to areas adjacent to the struts, as
convection dominates over diffusion. Feenstra and Taylor [59], in
their earlier work, utilize a sequential porohyperelastic transport
approach and do not apply any of these assumptions. In particular,
they calculate the interstitial ﬂuid velocity ﬁeld using a stent
deployment simulation, rather than assuming it is known a priori.
A common difﬁculty with turning to higher dimensional models isthe increased computational cost associated with accounting for
multiple space scales. To overcome this, Vergara and Zunino [60]
proposed a model reduction strategy to derive approximate
boundary conditions that signiﬁcantly reduce the computational
burden.
Only two groups thus far have attempted to model the coupled
problem of drug release from DESs and arterial deposition which
involves a nonlinear saturable binding model. Tzafriri et al. use
the formula (5) to describe the release of drug from two types of
non-erodible stents (Cypher and Nevo) and from this the rate of
change of mass is easily derived:
dMstent
dt
¼ Kf0Mf0 exp Kf0 t
  Qsus
2
ﬃﬃ
t
p : ð34Þ
Within the media layer of the tissue they utilise the one-
dimensional convection–diffusion–reaction equation (in a
cylindrical co-ordinate system)
@C
@t
þ @Cb
@t
þ @Cbns
@t
¼ D @
2C
@r2
þ D
r
@C
@r
 v @C
@r
ð35Þ
and couple the release to the tissue equation through the following
ﬂux boundary condition:
 D @C
@r
þ vC ¼  fwall
SlumenAdrug
dMstent
dt
ð36Þ
¼ Fluxin; ð37Þ
where fwall; Slumen and Adrug are the efﬁciency factor for delivery into
the arterial wall, the surface area of the blood wall interface and the
drug’s molecular weight, respectively. The time rate of change of
the concentrations of speciﬁcally bound drug (@Cb=@t) and of the
non-speciﬁcally bound drug (@Cbns=@t) are given by (24, 25). They
assumed C ¼ 0 at the perivascular end and simulated the solution
numerically. In addition to this, by assuming that once drug concen-
trations have traversed the thickness of the arterial wall, concentra-
tion gradients in the wall quasi-statically track the declining rate of
drug elution, they solved the steady-state version of the model and
also neglected the curvature term. They ﬁnd that once quasi-steady
state is established, the content of free drug in coronary tissue
should proportionally track the rate of drug elution:
CfreeðtÞ ¼ AdrugFluxinðtÞqtissuev
1 1 exp Pef g
Pe
	 

; ð38Þ
where qtissue and Pe are the density of wet arterial tissue and the
Peclet number, respectively. By probing their analytical solution
they conclude, in conjunction with the numerical results, that the
persistence time of receptor saturation and effect is more sensitive
to duration of elution than to eluted amount. Consequently, dose
escalation is inefﬁcient at compensating for sub-optimal duration
of elution, so that stent manufacturer’s efforts should be concen-
trated on sustaining elution rather than elevating the load. Interest-
ingly, by comparison with experiments, they ﬁnd that fwall is
approximately 0.06 and 0.16 for Cypher and Nevo stents, respec-
tively, suggesting that a signiﬁcant portion of drug is lost.
Most recently, Bozsak et al. [44] attempted to answer three key
questions of industrial and clinical interest: Why do some drugs
coated on stents perform differently from others when their prop-
erties appear to be similar? How important is the inclusion of a
multi-layered structure of the arterial wall? Which type of reaction
(saturable nonlinear two species model or non-saturable one
species model) captures the binding effect in the tissue? The
authors consider a two-dimensional model where drug transport
in the drug coating is governed by diffusion only and drug
transport through the arterial wall is governed by the convec-
tion–diffusion reaction Eq. (15) where the reaction takes the form
(24), i.e. a non-linear saturable binding model. In addition, Bozsak
S. McGinty /Mathematical Biosciences 257 (2014) 80–90 89et al. model the drug transport in the lumen with a convection–
diffusion equation where the blood ﬂow is assumed steady.
Kedem–Katchalsky membrane conditions are utilised to describe the
concentration discontinuity across the thin endothelium and internal
elastic lamina and continuity of ﬂux conditions are also employed
(essentially the two-dimensional equivalent of (26) and (27)).
Three different conditions are considered at the far adventitia,
these being inﬁnite sink, zero ﬂux and Robin-type conditions. It
was found that the choice of boundary condition had no signiﬁcant
effect on the results. The governing equations were discretized by
means of the ﬁnite element method (FEM) using the commercial
software package COMSOL Multiphysics 4.3. They conclude that
the one layer model (which includes only the medial layer and
neglects the sub-endothelial space) is incapable of predicting the
observed backﬂow that enters the sub-endothelial space in the
two layer model. Furthermore, the peak tissue concentration is
underestimated by 30% and as the thickness of the sub-endothelial
space increases (representing diseased arteries) the difference
between the one and two layer models become more pronounced.
Comparing the two different binding models, the authors note they
are comparable at very early times but the peak concentration pre-
dicted by the equilibrium model occurs considerably later and is
signiﬁcantly higher. Matching the prediction of drug accumulation
by the equilibrium model to that of the saturable model requires a
reduction in partition coefﬁcient while matching drug residence
time requires an increase. Clearly, both cannot be achieved simul-
taneously. Finally the authors conclude that the difference in bind-
ing properties between paclitaxel and sirolimus are due to the
greater convection-dominated transport of paclitaxel compared
with sirolimus. For paclitaxel, the drug is initially predominantly
in the free state and invades the media driven by plasma ﬂow in
the arterial wall since the timescale for convection is faster than
that for binding. With rising levels of free drug in the wall, the
binding rate increases. Once all binding sites are saturated any
excess drug is washed out and when the stent polymer is empty
and the wall is devoid of excess drug, the transport becomes dom-
inated by unbinding. However, for sirolimus, the initial dominating
process is binding and so the binding sites become very rapidly
occupied. Once they become exhausted, a more convection-driven
phase takes over.
5. Discussion
In this article we have attempted to provide a comprehensive
review of the modelling approaches adopted to study the release
of drug from arterial stents and the redistribution in arterial tissue.
Despite the high level of complexity involved, over the past decade
real progress has been made in attempting to understand the
mechanism(s) governing the release of drug from DESs and also
in understanding the transport and binding properties of drugs in
arterial tissue. Stimulated by early experimental works [33–37]
researchers from across the globe have become increasingly inter-
ested in attempting to model these processes. A combination of
approaches have been adopted. Some authors have focussed on
trying to accurately characterise the release of drug from DES in
controlled in vitro experiments while others have applied simple
models to the in vivo situation. A number of groups have focussed
speciﬁcally on drug transport through arterial tissue and in trying
to understand the complex binding process that takes place as well
as the relative importance of convection, diffusion and reaction.
While simpliﬁed one-dimensional models can provide useful
insights into this problem, ultimately three-dimensional models
which capture the full complex geometry of the stent and the arte-
rial wall may be required. The existing three-dimensional models
in the literature all make certain simplifying assumptions, whether
it be in idealising the stent geometry, or in neglecting convection,diffusion or binding, or in considering only single or bi-layer arte-
rial walls. Thus there is an opportunity to increase the sophistica-
tion of the three-dimensional models, whether it be incrementally
or all at once. However, caution must be exercised to ensure that
the results of the simulations are not subject to high uncertainty,
in which case the ﬁdelity of the results may be called into question.
Thus there is still a role for simpliﬁed models, especially those
which can admit analytical solutions, in helping to ascertain the
numerous parameters of the increasingly complex models. Many
of the parameters of the most involved models are extremely difﬁ-
cult (or impossible) to measure experimentally in the living system
and thus new methods for approximating these parameters should
be developed by modellers and experimentalists working in
tandem. Some progress has been made on this issue with experi-
mental data complemented with values from ﬁber matrix and pore
theory [57,44].
Presently, the stent manufacturers are predominantly con-
cerned with mechanical integrity of the device and as such the
stent design is usually the ﬁrst consideration. The stent must be
ﬂexible and expandable and stay in situ after deployment. During
the expansion process the stent should undergo minimum short-
ening and after implantation should conform to the natural geom-
etry of the vessel without any unnatural straightening [5].
Circumferential strength is another key component; without this
the stent will collapse under the strain of the artery. Furthermore,
the materials used must be bio-compatible and must not fracture.
But it is no good having a stent which is mechanically sound but
does not elute drug in a favourable fashion. The release of the drug
must be controlled so that it elutes over a deﬁned period of time
and, furthermore, the drug concentration in the arterial wall
should ideally be maintained between therapeutic and toxic levels
over and beyond the period of release. Taking this into account, it
would seem that the drug release and uptake is intrinsically linked
to the stent design. Ideally the stent should be optimised, both in
terms of the mechanical design as well as drug loading so that
the required clinical outcomes are realised. This optimisation is
further complicated by the observed variation in lesion composi-
tion and other underlying health conditions of the patient. Thus
a single optimised stent design is simply unrealistic, but it may
well be possible to develop an optimised stent for a set of different
situations. Certainly, in light of increased understanding of the
drug release and arterial binding processes there is an opportunity
to design stents to achieve desired clinical outcomes.
Stent manufacturers have demonstrated consideration of
clinical outcomes in recent stent designs which have included bio-
degradable polymers, fully biodegradable structures and polymer
free designs. Whilst these tackle the problem of having a perma-
nent polymer in situ, the clinical outcomes have been observed
to be largely equivalent to their non-erodible polymer coated
counterparts [61]. To date there appears to be limited mathemati-
cal modelling of these more advanced stents which couples drug
release with arterial transport: the only example seems to be the
work of Borghi et al. [58]. Such modelling may shed light on how
these devices may be improved to realise the desired clinical
outcome.
Acknowledgements
The author would like to thank Professor Sean McKee
(Department of Mathematics and Statistics), Doctor Christopher
McCormick (Biomedical Engineering) and Doctor Marcus Wheel
(Mechanical and Aerospace Engineering), all from the University
of Strathclyde, as well as Doctor Simon Kennedy (The Institute of
Cardiovascular and Medical Sciences, University of Glasgow) and
Professor Keith Oldroyd (Consultant Interventional Cardiologist,
Golden Jubilee National Hospital, Glasgow) for their helpful
90 S. McGinty /Mathematical Biosciences 257 (2014) 80–90suggestions and advice. He would also like to acknowledge the
funding provided by EPSRC under Grant No. EP/J007242/1.
References
[1] G.G. Stefanini, D.R. Holmes, Drug-eluting coronary artery stents, N. Engl. J.
Med. 368 (2013) 254–265.
[2] A.R. Tzafriri, A. Groothuis, G.S. Price, E.R. Edelman, Stent elution rate
determines drug deposition and receptor-mediated effects, J. Control. Release
161 (2012) 918–926.
[3] I. Akin, H. Schneider, H. Ince, S. Kiche, T. Rehders, T. Chatterjee, C. Nienaber,
Second- and third-generation drug-eluting coronary stents: progress and
safety, Herz 2011 (26) (2011) 190–197.
[4] A.S. Puranik, E.R. Dawson, N.A. Peppas, Recent advances in drug eluting stents,
Int. J. Pharm. 441 (2013) 665–679.
[5] W. Khan, S. Farah, A.J. Domb, Drug eluting stents: developments and current
status, J. Control. Release 161 (2012) 703–712.
[6] S. McGinty, S. McKee, R.M. Wadsworth, C. McCormick, Modelling drug-eluting
stents, Math. Med. Biol. 28 (2011) 1–29.
[7] G. Pontrelli, F. de Monte, Mass diffusion through two-layer porous media: an
application to the drug-eluting stent, Int J. Heat Mass Trans. 50 (2007) 3658–
3669.
[8] P. Zunino, Multidimensional pharmacokinetic models applied to the design of
drug-eluting stents, Cardiovasc. Eng.: Int. J. 4 (2) (2004) 181–191.
[9] S. McGinty, S. McKee, C. McCormick, M. Wheel, Release mechanism and
parameter estimation in drug-eluting stent systems: analytical solutions of
drug release and tissue transport, Math. Med. Biol. http://dx.doi.org/10.1093/
imammb/dqt025.
[10] H.Q. Zhao, D. Jayasinghe, S. Hossainy, L.B. Schwartz, A theoretical model to
characterize the drug release behavior of drug-eluting stents with durable
polymermatrix coating, J. Biomed.Mater. Res., Part A 100A (1) (2012) 120–124.
[11] S. Hossainy, S. Prabhu, A mathematical model for predicting drug release from
a biodurable drug-eluting stent coating, J. Biomed. Mater. Res., Part A 87A
(2008) 487–493.
[12] J. Siepmann, F. Siepmann, Modelling of diffusion controlled drug delivery, J.
Control. Release 161 (2012) 351–362.
[13] T. Higuchi, Rate of release of medicaments from ointment bases containing
drugs in suspension, J. Pharm. Sci. 50 (1961) 874–875.
[14] J. Crank, The Mathematics of Diffusion, Clarendon Press, Oxford, 1975.
[15] G. Pontrelli, A.D. Mascio, F. de Monte, Local mass non-equilibrium dynamics in
multi-layered porous media: application to the drug-eluting stent, Int. J. Heat
Mass Trans. 66 (1) (2013) 844–854.
[16] J. Siepmann, F. Siepmann, Mathematical modelling of drug delivery, Int. J.
Pharm. 364 (2008) 328–343.
[17] S. Fredenberg, M.W.M. Reslow, A. Axelsson, The mechanisms of drug release in
poly(lactic-co-glycolic acid)-based drug delivery systems – a review, Int. J.
Pharm. 415 (2011) 34–52.
[18] S. Prabhu, S. Hossainy, Modeling of degradation and drug release from a
biodegradable stent coating, J. Biomed. Mater. Res., Part A 80A (3) (2007) 732–
741.
[19] J. Siepmann, A. Gopferich, Mathematical modeling of bioerodible, polymeric
drug delivery systems, Adv. Drug Deliv. Rev. 48 (2–3) (2001) 229–247.
[20] J. Heller, R.W. Baker, Theory and practice of controlled drug delivery from
bioerodible polymers, in: R.W. Baker (Ed.), Controlled Release of Bioactive
Materials, Academic Press, New York, 1980.
[21] P.I. Lee, Diffusional release of a solute from a polymeric matrix approximate
analytical solution, J. Membrane Sci. 7 (1980) 255–275.
[22] A. Thombre, Theoretical aspects of polymer biodegradation: mathematical
modeling of drug release and acid-catalyzed poly(ortho-ester) biodegradation,
in: M. Vert, J. Feijen, A. Albertsson, G. Scott, E. Chiellini (Eds.), Biodegradable
Polymers and Plastics, Redwood Press, 1992.
[23] A. Joshi, K.J. Himmelstein, Dynamics of controlled release from bioerodible
matrices, J. Membrane Sci. 15 (1991) 95–104.
[24] S.N. Rothstein, W.J. Federspiel, S.R. Little, A uniﬁed mathematical model for the
prediction of controlled release from surface and bulk eroding polymer
matrices, Biomaterials 30 (8) (2009) 1657–1664.
[25] J.S. Soares, P. Zunino, A mixture model for water uptake, degradation, erosion
and drug release from polydisperse polymeric networks, Biomaterials 31 (11)
(2010) 3032–3042.
[26] F. Rossi, T. Casalini, E.R.M. Masi, G. Perale, Bioresorbable polymer coated drug
eluting stent: a model study, Mol. Pharmacol. 9 (7) (2012) 1898–1910.
[27] L. Formaggia, S. Minisini, P. Zunino, Modeling polymeric controlled drug
release and transport phenomena in the arterial tissue, Math. Mod. Meth. Appl.
Sci. 20 (10) (2010) 1759–1786.
[28] J. Siepmann, F. Siepmann, Mathematical modeling of drug dissolution, Int. J.
Pharm. 453 (2013) 12–24.
[29] C. Yang, H.M. Burt, Drug-eluting stents: factors governing local
pharmacokinetics, Adv. Drug Deliv. Rev. 58 (2006) 402–411.
[30] F. de Monte, G. Pontrelli, S. Becker, Drug release in biological tissues, in: S.M.
Becker, A.V. Kuznetsov (Eds.), Transport in Biological Media, Elsevier Science
BV, Amsterdam, 2013.
[31] A.D. Levin, N. Vukmirovic, C.W. Hwang, E.R. Edelman, Speciﬁc binding to
intracellular proteins determines arterial transport properties for rapamycin
and paclitaxel, Proc. Natl. Acad. Sci. USA 101 (25) (2004) 9463–9467.[32] W. Hwang, D. Wu, E.R. Edelman, Physiological transport forces govern drug-
distribution for stent based delivery, Circulation 104 (7) (2001) 600–605.
[33] C.J. Creel, M.A. Lovich, E.R. Edelman, Arterial paclitaxel distribution and
deposition, Circ. Res. 86 (2000) 874–884.
[34] C. Hwang, D. Wu, E.R. Edelman, Physiological transport forces govern drug
distribution for stent-based delivery, Circulation 104 (5) (2001) 600–605.
[35] M. Lovich, M. Philbrook, S. Sawyer, E. Weselcouch, E.R. Edelman, Arterial
heparin deposition: role of diffusion, convection and extravascular space, Am J.
Physiol. 256 (6) (1998) 2236–2242 (2).
[36] C. Hwang, E.R. Edelman, Arterial ultrastructure inﬂuences transport of locally
delivered drugs, Circ. Res. 90 (7) (2002) 826–832.
[37] M. Lovich, E.R. Edelman, Computational simulations of local vascular heparin
deposition and distribution, Am J. Physiol. Heart Circ. Physiol. 271 (5) (1996)
2014–2024.
[38] M. Horner, S. Joshi, V. Dhruva, S. Sett, S.F.C. Stewart, A two-species drug
delivery model is required to predict deposition from drug-eluting stents,
Cardiovasc. Eng. Technol. 1 (3) (2010) 225–234.
[39] J.P. Abraham, J.M. Gorman, E.M. Sparrow, J.R. Stark, R.E. Kohler, A mass transfer
model of temporal drug deposition in artery walls, Int. J. Heat Mass Trans. 58
(2013) 632–638.
[40] G. Pontrelli, F. de Monte, Modeling of mass dynamics in arterial drug-eluting
stents, J. Porous Media 12 (1) (2009) 19–28.
[41] G. Pontrelli, F. de Monte, A multi-layer porous wall model for coronary drug-
eluting stents, Int J. Heat Mass Trans. 53 (2010) 3629–3637.
[42] D.V. Sakharov, L.V. Kalachev, D.C. Rijken, Numerical simulation of local
pharmacokinetics of a drug after intravascular delivery with an eluting
stent, J. Drug Target. 10 (2002) 507–513.
[43] A.R. Tzafriri, A.D. Levin, E.R. Edelman, Diffusion-limited binding explains
binary dose response for local arterial and tumour drug delivery, Cell
Proliferat. 42 (2009) 348–363.
[44] F. Bozsak, J. Chomaz, A.I. Barakat, Modeling transport of drugs eluted from
stents: physical phenomena driving drug distribution in the arterial wall,
Biomech. Model Mechanobiol. 13 (2) (2014) 327–347, http://dx.doi.org/
10.1007/s10237-013-0546-4.
[45] D.A. Lauffenburger, J.J. Linderman, Receptors, Oxford University Press, New
York, 1993.
[46] W. Zhu, T. Masaki, A.K. Cheung, S.E. Kern, In-vitro release of rapamycin from a
thermosensitive polymer for the inhibition of vascular smooth muscle cell
proliferation, J. Bioequiv. Availab. 1 (2009) 3–12.
[47] A.D. Levin, M. Jonas, C.W. Hwang, E.R. Edelman, Local and systemic drug
competition in drug-eluting stent tissue deposition properties, J. Control.
Release 109 (2005) 236–243.
[48] B.E. Bierer, P.S. Patilla, R.F. Standaert, L.A. Herzenberg, S.J. Burakoff, G. Crabtree,
S. Schreiber, In-vitro release of rapamycin from a thermosensitive polymer for
the inhibition of vascular smooth muscle cell proliferation, Proc. Natl. Acad.
Sci. USA 87 (1990) 9231–9235.
[49] A. Tzafriri, N. Vukmirovic, V. Kolachalama, I. Astaﬁeve, E.R. Edelman, Lesion
complexity determines arterial drug distribution after local drug delivery, J.
Control. Release 142 (3) (2010) 332–338.
[50] S. McGinty, S. McKee, R.M. Wadsworth, C. McCormick, Modeling arterial wall
drug concentrations following the insertion of a drug-eluting stent, SIAM J.
Appl. Math. 73 (6) (2014) 2004–2028.
[51] M. Grassi, G. Pontrelli, L. Teresi, G. Grassi, L. Comel, A. Ferluga, L. Galasso, Novel
design of drug delivery in stented arteries: a numerical comparative study,
Math. Biosci. Eng. 6 (3) (2009) 493–508.
[52] J.M. Weiler, E.M. Sparrow, R. Ramazani, Mass transfer by advection and
diffusion from a drug-eluting stent, J. Heat Mass Trans. 55 (2012) 1–7.
[53] R. Mongrain, I. Faik, R. Leask, J. Rodes-Cabau, E. Larose, O. Bertrand, Effects of
diffusion coefﬁcients and struts apposition using numerical simulations for
drug eluting coronary stents, J. Biomech. Eng. 129 (2007) 733–742.
[54] P. Zunino, C. D’Angelo, L. Petrini, C. Vergara, C. Capelli, F. Migliavacca,
Numerical simulation of drug eluting coronary stents: mechanics, ﬂuid
dynamics and drug release, Comput. Methods Appl. Mech. Eng. 198 (2009)
3633–3644.
[55] G. Vairo, M. Ciofﬁ, R. Cottone, G. Dubini, F. Migliavacca, Drug release from
coronary artery stents: a multidomain approach, J. Biomech. 43 (2010) 1580–
1589.
[56] C. D’Angelo, P. Zunino, A numerical study of the interaction of blood ﬂow and
drug release from cardiovascular stents, in: Numerical Mathematics and
Advanced Applications, Proceedings of ENUMATH 2007, Graz, Austria, 2008,
pp. 75–82.
[57] L. Formaggia, A. Quarteroni, A. Veneziani, Cardiovascular Mathematics –
Modeling and Simulation of the Circulatory System, Springer-Verlag Italia,
Milano, 2009.
[58] A. Borghi, E. Foa, R. Balossino, F. Migliavacca, G. Dubini, Modelling drug elution
from stents: effects of reversible binding in the vascular wall and degradable
polymeric matrix, Comput. Methods Biomech. Biomed. Eng. 11 (2008) 367–
377.
[59] P.H. Feenstra, C.A. Taylor, Drug transport in artery walls: a sequential
porohyperelastic-transport approach, CMBBE 12 (3) (2009) 263–276.
[60] C. Vergara, P. Zunino, Multiscale boundary conditions for drug release
from cardiovascular stents, Multiscale Model. Simul. 7 (2) (2008) 565–
588.
[61] A.M. Sammel, D. Chen, N. Jepson, New generation coronary stent technology –
is the future biodegradable?, Heart Lung Circul 22 (7) (2013) 495–506.
